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A role for Bruton’s tyrosine kinase (Btk) in platelet activation by
collagen
L.S. Quek*, J. Bolen† and S.P. Watson*
Bruton’s tyrosine kinase (Btk) is essential for normal 
B-cell receptor signalling. The lack of expression of
functional Btk in humans leads to the B-cell deficiency
X-linked agammaglobulinaemia (XLA). We report here
that Btk is also important for signalling via the collagen
receptor glycoprotein VI (GPVI) in platelets. GPVI is
coupled to the Fc receptor g chain (FcRg). The FcRg-
chain contains a consensus sequence known as the
immune-receptor tyrosine-based activation motif
(ITAM). Tyrosine phosphorylation of the ITAM upon
GPVI stimulation is the initial step in the regulation of
phospholipase C g2 (PLCg2) isoforms via the tyrosine
kinase p72Syk (Syk) in platelets. Here we show that
collagen and a collagen-related peptide (CRP), which
binds to GPVI but does not bind to the integrin a2b1,
induced Btk tyrosine phosphorylation in platelets.
Aggregation, dense granule secretion and calcium
mobilisation were significantly diminished but not
completely abolished in platelets from XLA patients in
response to collagen and CRP. These effects were
associated with a reduction in tyrosine phosphorylation
of PLCg2. In contrast, aggregation and secretion
stimulated by thrombin in Btk-deficient platelets were
not significantly altered. Our results demonstrate that
Btk is important for collagen signalling via GPVI, but is
not essential for thrombin-mediated platelet activation.
Addresses: *Department of Pharmacology, University of Oxford,
Mansfield Road, Oxford OX1 3QT, UK. †Department of Oncology,
Hoechst Marion Roussel, Route 202-206, P.O. Box 6800,
Bridgewater, New Jersey 08807, USA.
Correspondence: L.S. Quek
E-mail: lynn.quek@st-johns.oxford.ac.uk
Received: 2 July 1998
Revised: 14 August 1998
Accepted: 8 September 1998
Published: 28 September 1998
Current Biology 1998, 8:1137–1140
http://biomednet.com/elecref/0960982200801137
© Current Biology Ltd ISSN 0960-9822
Results and discussion
Tyrosine phosphorylation of Btk in stimulated platelets
Treatment of platelets with CRP or collagen induced sig-
nificant Btk tyrosine phosphorylation with a lag phase of
approximately 20–45 seconds (Figure 1a,b). Btk also
became tyrosine phosphorylated by 20 seconds (the earli-
est time point investigated) following the addition of
thrombin (Figure 1c). Btk co-immunoprecipitated with
the Src-family kinase p53/56Lyn (Lyn) in thrombin-stimu-
lated platelets (Figure 1c). A weak association between
Btk and Lyn was also observed in CRP-stimulated
platelets (data not shown). The cytokine thrombopoietin
(TPO), which has been shown to signal via Janus tyrosine
kinases (JAKs) in platelets [1], did not induce Btk tyrosine
phosphorylation (Figure 1d). Thus, Btk tyrosine phospho-
rylation occurs in platelets downstream of GPVI, which
signals via an ITAM, and downstream of the G-protein-
coupled thrombin receptor.
Functional responses of Btk-deficient XLA platelets
To investigate the functional importance of Btk in
platelets, studies were performed using platelets obtained
from Btk-deficient XLA donors. XLA platelet lysates
were immunoblotted using an anti-Btk antiserum to
confirm the absence of Btk expression (data not shown).
Aggregation of Btk-deficient platelets stimulated by CRP
was markedly reduced in XLA donors compared with con-
trols over a range of peptide concentrations (one experi-
ment representative of results from three different XLA
donors is shown in Figure 2a). In two out of three XLA
donors, CRP (1–5 µg/ml) stimulated shape change,
detected as a small increase in optical density, but did not
stimulate aggregation. These concentrations of CRP
induced rapid and full aggregation of control platelets. A
high concentration of CRP (5 µg/ml) induced aggregation
of platelets from the other XLA donor. This aggregation
was significantly reduced compared with control platelets,
however (data not shown).
Btk-deficient XLA platelets also showed an attenuated
aggregatory response to submaximal concentrations of col-
lagen (0.25–20 µg/ml). One experiment representative of
results from four different donors is shown in Figure 2b.
The differences in aggregation responses between XLA
and control platelets stimulated by collagen were less
marked than in the CRP-stimulated samples. This might
reflect the fact that collagen binds to platelet surface
receptors in addition to CRP, notably the integrin α2β1. In
contrast, aggregation of Btk-deficient platelets in response
to low and high concentrations of thrombin was not signif-
icantly different from controls over a range of concentra-
tions. One experiment representative of results from three
different XLA donors is shown in Figure 2c.
Platelet dense granules contain several inflammatory and
haemostatic mediators, including 5-hydroxytryptamine
(5HT), that are secreted upon activation. Measurements
of the quantity of [3H]5HT secretion, expressed as a
percentage of the total incorporated [3H]5HT, provide an
indication of platelet activation. CRP stimulated
23.8 ± 4.0% (mean ± standard error; SE) [3H]5HT secre-
tion in control platelets, but only stimulated 3.3æ 1.1%
secretion in XLA platelets (n = 5, p < 0.01). Collagen stim-
ulated 40.0 ± 2.4% secretion in control platelets whereas it
stimulated 9.8 ± 3.6% secretion in Btk-deficient XLA
platelets (n = 5, p < 0.01). There was no significant differ-
ence between XLA and control platelets when they were
stimulated by thrombin (Figure 2d). A reduction in
[3H]5HT secretion was observed over a full range of con-
centrations of CRP and collagen (data not shown). The
degree of [3H]5HT-loading of XLA and control platelets
was equivalent.
The impairment of secretion was slightly greater when
platelets were stimulated with CRP than with collagen.
Nevertheless, there was an approximately 75% decrease
in secretion induced by high concentrations of collagen
compared with controls. Although these results are
similar to those obtained with platelet aggregation, high
concentrations of agonist did not elicit a recovery of
secretion in Btk-deficient platelets. This may be due to
differences in conditions under which the experiments
were performed, because aggregation studies were
carried out in the absence of EGTA and indomethacin,
whereas secretion experiments were in the presence of
1 mM EGTA and 10 µM indomethacin, which inhibit
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Figure 1
Tyrosine phosphorylation of Btk in stimulated
platelets. Western blots of Btk
immunoprecipitates (IP) were probed with anti-
phosphotyrosine (anti-PY), anti-Btk or anti-Lyn
antibodies. Btk was tyrosine phosphorylated in
platelets stimulated with (a) CRP (1 µg/ml), 
(b) collagen (100 µg/ml), and (c) thrombin
(1unit/ml) for the indicated times. In (c) Lyn is
shown to co-immunoprecipitate with Btk.
(d) TPO (500 ng/ml) treatment for 180 sec did
not induce significant increase in Btk tyrosine
phosphorylation. Indomethacin (10 µM) and
EGTA (1 mM) were added to platelet
suspensions immediately before the beginning
of the experiment. One experiment
representative of 3–12 similar studies is shown.
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Figure 2
Functional platelet responses in XLA and control platelets. Btk-
deficient XLA platelets were markedly less responsive to aggregation
induced by (a) CRP (1.0 and 5.0 µg/ml) and (b) collagen
(0.25–20 µg/ml) compared with control platelets. (c) XLA platelet
responses to thrombin (0.01–1.0 unit/ml) were not significantly
different from those of control platelets. The optical density (OD) of
platelet suspensions was measured in an aggregometer with stirring at
1300 rpm in the absence of indomethacin and EGTA. Results
presented are representative of experiments using platelets from a
minimum of three different XLA and three control donors. (d) XLA
platelets had significantly reduced [3H]5HT secretion in response to
CRP (1 µg/ml) and to collagen (100 µg/ml) compared with controls
(the two asterisks indicate p < 0.001), but there was no significant
difference between XLA and control responses to thrombin (1 unit/ml).
Indomethacin (10 µM) and EGTA (1 mM) were added to platelet
suspensions immediately before the start of the experiment. Results
are shown as mean ± SE from five different experiments.
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positive feedback signalling via engagement of the 
fibrinogen receptor αIIbβ3 and cyclooxygenase activation,
respectively. Together with the results from aggregation
assays, these results demonstrate an important role for
Btk in platelet activation by CRP and collagen, but not
by thrombin.
Tyrosine phosphorylation and activation of PLCg2 in
Btk-deficient XLA platelets
PLCγ2 is the dominant form of PLCγ in platelets and
undergoes marked tyrosine phosphorylation in response to
collagen [2]. Tyrosine phosphorylation of PLCγ2 in
response to CRP was significantly reduced in Btk-defi-
cient XLA platelets relative to controls at all times from 20
to 180 seconds (Figure 3a). This result is representative of
experiments from four different XLA donors. A similar
decrease in PLCγ2 tyrosine phosphorylation in XLA
platelets was seen following stimulation with collagen
(Figure 3b). The degree of attenuation of PLCγ2 tyrosine
phosphorylation in platelets stimulated with CRP for
90 seconds was 32 ± 13% (mean ± SE) relative to controls
(n = 4, p < 0.05). In contrast, tyrosine phosphorylation of
Syk, which lies upstream PLCγ2 [3], was not reduced in
CRP-stimulated XLA platelets compared with controls
(data not shown).
A further indicator of PLCγ2 activation in collagen-stimu-
lated and CRP-stimulated platelets is the mobilisation of
calcium from intracellular stores. In the presence of 1 mM
EGTA, XLA platelets loaded with the calcium-sensing
dye Fura2-AM showed very little response to CRP and a
diminished response to collagen compared with the robust
calcium mobilisation responses seen in control platelets
(Figure 4). The reduced mobilisation of intracellular
calcium is consistent with the decreased tyrosine phospho-
rylation of PLCγ2 and the reduced aggregatory and secre-
tory responses observed in platelets from XLA donors.
The reduced tyrosine phosphorylation of PLCγ2 in CRP-
stimulated and collagen-stimulated XLA platelets 
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Figure 3
Reduced tyrosine phosphorylation of PLCγ2
stimulated by CRP and collagen (Col) in XLA
platelets. Western blots of anti-PLCγ2
immunoprecipitates (IP) were probed with
anti-phosphotyrosine (anti-PY) and anti-
PLCγ2 antibodies. (a) Tyrosine
phosphorylation of PLCγ2 stimulated by CRP
(1 µg/ml) was reduced in XLA platelets
compared with control platelets over a
timecourse of 180 sec. This result is
representative of experiments using two
different XLA platelet samples. (b) A
reduction in PLCγ2 tyrosine phosphorylation
stimulated by collagen at low (10 mg/ml) and
high (100 µg/ml) concentrations and CRP
(1 µg/ml) was observed in platelets from XLA
patients compared with controls.
Indomethacin (10 µM) and EGTA (1 mM)
were added to platelet suspensions
immediately before the beginning of the
experiment. The reduction in tyrosine
phosphorylation of PLCγ2 was observed
consistently in CRP-stimulated platelets from
four different XLA donors compared with
platelets from control donors. Densitometric
analysis of the blots showed a reduction in
PLCγ2 tyrosine phosphorylation in XLA
platelets to 32 ± 13% (mean ± SE) of the
levels in controls (n = 4, p < 0.05).
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Figure 4
Calcium mobilisation in XLA and control
platelets stimulated by CRP and collagen.
Platelets were loaded with Fura2-AM dye.
EGTA (1 mM) was added to the platelet
suspension immediately before the beginning
of the experiment. (a) XLA platelets showed
no significant calcium mobilisation in response
to CRP (1 µg/ml) compared with control
platelets. (b) Calcium mobilisation in XLA
platelets in response to collagen (100 µg/ml)
was reduced compared with control platelets.
These results are representative of
experiments using platelets from two different
XLA patients.
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compared with controls provides a biochemical basis for
the functional defects apparent in Btk-deficient platelets.
This is consistent with earlier reports of inhibition of
PLCγ tyrosine phosphorylation in Btk-deficient chick
DT40 B cells [4]. A recently published study by Fluckiger
et al. [5] reports, however, that tyrosine phosphorylation of
PLCγ2 is not impaired in Btk-deficient B-cell lines
derived from XLA patients. These B cells nonetheless
have reduced production of inositol trisphosphate (IP3)
and a reduced calcium influx. The explanation for these
contrasting results is not known, although it could reflect
either the presence of different sites of tyrosine phospho-
rylation on PLCγ2, distinct intracellular ‘pools’ of the
phospholipase in different cell lines, or differences due to
the stage of development of the B cells. Since PLCγ2 tyro-
sine phosphorylation is only partially reduced in Btk-defi-
cient platelets, there must be alternative pathways that
regulate tyrosine phosphorylation of the phospholipase.
Other tyrosine kinases including Tec, a homologue of Btk
that is expressed in platelets [6], might partially substitute
for Btk in regulating the tyrosine phosphorylation of
PLCγ2 in XLA platelets, or might mediate tyrosine phos-
phorylation of the phospholipase independently of Btk.
Scharenberg et al. [7] have shown that the Src homology 2
(SH2) domain of Btk is important for tyrosine phosphory-
lation and activation of PLCγ2. The requirement for the
SH2 domain of Btk indicates that an interaction between
Btk and a phosphotyrosyl protein is important for PLCγ2
activation. Scharenberg et al. [7] suggest that Btk interacts
directly with PLCγ2 following tyrosine phosphorylation
by another tyrosine kinase. Such an interaction is then fol-
lowed by full tyrosine phosphorylation of PLCγ2 by Btk,
leading to activation of the phospholipase. As yet we have
no direct evidence to suggest that a similar mechanism
exists in collagen-stimulated and CRP-stimulated
platelets. It seems likely, however, that other tyrosine
kinases might have a role in regulating the tyrosine phos-
phorylation and activation of PLCγ2, either directly or via
indirect pathways involving Btk. For example, we have
evidence for an interaction in vivo between PLCγ2 and
the Src-family tyrosine kinase Lyn, (B.S. Gross and
S.P.W., unpublished observations). Furthermore, the asso-
ciation of Syk with PLCγ1 has been reported in B cells [8].
Much of the published work on Btk has centred upon its
signalling role in leukocytes. This study highlights a func-
tional role for Btk in platelets and demonstrates that Btk is
important for ITAM-mediated signalling pathways in
haematopoietic cells. We describe functional defects in
platelets that are deficient in Btk, and conclude that Btk
plays a crucial role during activation of platelets by CRP
and collagen by regulating tyrosine phosphorylation and
activation of PLCγ2. Btk is not essential for thrombin-
mediated platelet activation, however. The specific
involvement of Btk in GPVI signalling has important impli-
cations for our understanding of platelet physiology and
biochemistry. Platelets have a large number and range of
receptors which mediate activation during haemostasis.
This may explain why there are no reports of XLA patients
with severe haemostatic problems despite the partial loss of
their response to collagen. In contrast, GPVI-deficient
patients occasionally suffer from severe, acute bleeding
events [9]. Nevertheless, a full clinical assessment is
required to investigate the increased risk of severe bleed-
ing episodes, especially during incidences of physical
trauma in XLA patients.
There are several points which we have yet to clarify,
namely the biochemical mechanism by which Btk regu-
lates PLCγ2 tyrosine phosphorylation and activation, and
also the mechanisms by which Btk tyrosine phosphoryla-
tion and activation is regulated. The clarification of the
these aspects of our work will have important implications
for our understanding of ITAM-mediated signalling, in
particular the mechanisms of regulation of PLCγ2 and Tec
family kinases in platelets and other haematopoietic cells.
Supplementary material
Additional methodological details are published with this paper on
the internet.
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Materials and methods
Reagents
Sources of Type 1 collagen, CRP (GCP*(GPP)10GCP*G, in single-
letter amino-acid code where P* indicates hydroxyproline; the peptide
is cross-linked via the two cysteine residues) and bovine thrombin has
been described [S1]. Thrombopoietin was from Genzyme Diagnostics.
Anti-Btk polyclonal antiserum was generated as described [S2]. Anti-
PLCγ2 polyclonal antiserum was a gift from Young-Han Lee [S3]. Anti-
phosphotyrosine monoclonal antibody 4G10 was from Upstate
Biotechnologies. Sources of protein-A–Sepharose beads, polyvinyld-
ifluoride (PVDF) membranes, horseradish peroxidase (HRP)-conju-
gated secondary antibodies and the enhanced chemoluminescence
(ECL) kit have been described [S1]. [3H]5HT binoxalate was from NEN
Life Sciences. 
Preparation and activation of human platelets
Platelets were prepared from aspirin-free volunteers on the day of
experiment as described [S4] and used at a concentration of
1 × 109 cells/ml in modified Tyrode’s buffer (139 mM NaCl, 2.9 mM
KCl, 0.34 mM NaHPO4, 12 mM NaHCO3, 20 mM HEPES, 1 mM
MgCl2, pH 7.28 ); 10 µM indomethacin and 1 mM EGTA were added
to the platelet suspension immediately before stimulation, unless
stated otherwise. Stimulation of platelets with was carried out in a
Chronolog aggregometer at 37°C with continuous stirring (1200 rpm)
for 60 sec unless specified otherwise. Citrated blood samples were
obtained from XLA patients from the Immunology Clinic of the John
Radcliffe NHS Trust, and prepared as control platelets. Platelet con-
centration for XLA studies was 4 × 109 cells/ml unless stated other-
wise. Platelet densities in samples from XLA patients were matched
with those from control subjects.
Aggregation assay
Washed platelets were resuspended in modified Tyrode’s buffer to a
concentration of 1 × 108 platelets/ml and stimulated by a range of con-
centrations of agonist at 37°C in the absence of indomethacin and
EGTA, at high stirring speeds (1200 rpm) in a Chronolog aggregometer.
Aggregation of control and XLA platelets were recorded simultaneously.
[3H]5HT secretion assay
Platelet-rich plasma was loaded with [3H]5HT (0.5 µCi/ml) for 45 min
at 30°C. Platelets were then washed and resuspended in modified
Tyrode’s buffer to a concentration of 1 × 108 platelets/ml; 10 µM
indomethacin and 1 mM EGTA were added to the platelet suspension
immediately before stimulation in the aggregometer as described [S1].
Stimulation was stopped by brief microcentrifugation and the level of
[3H]5HT release into the supernatant was determined by scintillation
spectometry. Release of [3H]5HT was expressed as a percentage of
the total tissue content following subtraction of release under basal
conditions as described [S5].
Calcium fluorimetry
Platelets were loaded with Fura2-AM (3 µM/ml) for 1 h at 30°C. They
were resuspended in Tyrode’s buffer at a concentration of
1 × 108 platelets/ml following centrifugation. Measurement of intracellu-
lar calcium changes were made in the presence of 1mM EGTA (added
just before the beginning of the experiment), by fluorimetry using Perkin
Elmer FWinlab software.
Immunoprecipitation and western blotting
The immunoprecipitations were carried out as described [S1]. Endoge-
nous Btk was immunoprecipitated using 3 µl anti-Btk polyclonal anti-
serum. PLCγ2 was immunoprecipitated using 5 µl anti-PLCγ2 polyclonal
antiserum. Precipitates were resolved by SDS–PAGE and transferred
by semi-dry western blotting to PVDF membranes. Blocked membranes
were incubated with anti-phosphotyrosine antibody 4G10 at a dilution
of 1:1000 or with the anti-Btk polyclonal antibody (1:750). Blots were
incubated with HRP-conjugated secondary antibody and developed by
ECL. PVDF membranes were stripped using TBS-T containing 2% SDS
and 2% mercaptoethanol (twice at 80°C for 20 min), and washed and
re-blocked in 10% BSA before further immunoblotting.
References
S1. Gibbins JM, Asselin J, Farndale R, Barnes M, Law CL, Watson SP:
Tyrosine phosphorylation of the Fc receptor gamma-chain in
collagen-stimulated platelets. J Biol Chem 1996, 271:18095-9.
S2. Mahajan S, Fargnoli J, Burkhardt AL, Kut SA, Saouf SJ, Bolen JB: Src
family protein tyrosine kinases induce autoactivation of Btk. Mol
Cell Biol 1995, 15:5304-5311.
S3. Lee Y, Lee H, Lee S, Min D, Baek S, Kim Y, et al.: Down-regulation
of phospholipase C γ1 during differentiation of U937 cells. FEBS
Lett 1995, 358:105-108.
S4. Asselin J, Gibbins JM, Achison M, Lee YH, Morton LF, Farndale RW,
et al.: A collagen-like peptide stimulates tyrosine phosphorylation
of Syk and PLCγ2 in platelets independent of the integrin α2β1.
Blood 1997, 89:1235-1242.
S5. Nunn DL, Watson SP: A diacylglycerol kinase inhibitor, R59022
potentiates secretion by and aggregation of thrombin-stimulated
platelets. Biochem J 1987, 243:803-813.
Supplementary material
